Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Clinical Study of Orelabrutinib Combined With Lenalidomide and Rituximab (OR2) in the Treatment of Recurrent and Refractory CD20+ B-cell Lymphoma

NCT05014100 is registered in ClinicalTrials.gov with Puyang Oilfield General Hospital as lead sponsor.

NCT NCT05014100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05014100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Clinical Study of Orelabrutinib Combined With Lenalidomide and Rituximab (OR2) in the Treatment of Recurrent and Refractory CD20+ B-cell Lymphoma
Lead sponsor
Puyang Oilfield General Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
September 1, 2021
Completion date
September 30, 2023
Enrollment
55 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma